Arrowhead Pharmaceuticals (ARWR)
(Delayed Data from NSDQ)
$22.12 USD
+0.25 (1.14%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $22.12 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
ARWR 22.12 +0.25(1.14%)
Will ARWR be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ARWR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ARWR
Biotech Stock Roundup: BIIB's Q1 Results, ARWR Up on Data, INCY & BLUE Offer Updates
ARWR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ARWR
Arrowhead begins Phase 1/2a study of ARO-CFB for mediated kidney disease
First Week of December 20th Options Trading For Arrowhead Pharmaceuticals (ARWR)
Hepion ends Phase 2 study for NASH drug due to cash restraints
Athira Pharma appoints Javier San Martin as Chief Medical Officer
Wolfe upgrades Ionis to outperform, cites upcoming catalysts